Barbara Klencke is of TScan Therapeutics, Inc.. Currently has a direct ownership of 45,000 shares of TCRX, which is worth approximately $212,850. The most recent transaction as insider was on Sep 23, 2024, when has been sold 5,000 shares (Voting Common Stock) at a price of $5.29 per share, resulting in proceeds of $26,450. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45K
50.0% 3M change
n/a 12M change
Total Value Held $212,850

Barbara Klencke Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 23 2024
BUY
Open market or private purchase
$26,450 $5.29 p/Share
5,000 Added 10.0%
45,000 Voting Common Stock
Aug 26 2024
BUY
Open market or private purchase
$27,650 $5.53 p/Share
5,000 Added 11.11%
40,000 Voting Common Stock
Aug 23 2024
BUY
Open market or private purchase
$28,450 $5.69 p/Share
5,000 Added 12.5%
35,000 Voting Common Stock
Dec 14 2023
BUY
Open market or private purchase
$25,400 $5.08 p/Share
5,000 Added 14.29%
30,000 Voting Common Stock

Also insider at

SRRA
Sierra Oncology, Inc. Healthcare
EFTR
eFFECTOR Therapeutics, Inc. Healthcare
XNCR
Xencor Inc Healthcare
BK

Barbara Klencke

Solana Beach, CA

Track Institutional and Insider Activities on TCRX

Follow TScan Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TCRX shares.

Notify only if

Insider Trading

Get notified when an T Scan Therapeutics, Inc. insider buys or sells TCRX shares.

Notify only if

News

Receive news related to TScan Therapeutics, Inc.

Track Activities on TCRX